Vigil Neuroscience, INC Form 4 insider transactions
Director Mary Thistle of Vigil Neuroscience, Inc. was granted a stock option award for 18,068 shares on June 5, 2024.
Director Suzanne Louise Bruhn of Vigil Neuroscience, Inc. was granted a stock option award for 18,068 shares on June 5, 2024.
Director Gerhard Koenig of Vigil Neuroscience, Inc. received stock options for 18,068 shares at an exercise price of $3.38 on June 5, 2024.
Director Bruce Booth of Vigil Neuroscience, Inc. was granted stock options for 18,068 shares on June 5, 2024, under the company's 2021 Stock Option and Incentive Plan.
Samantha L. Budd Haeberlein, a director at Vigil Neuroscience, Inc., was granted stock options for 18,068 shares on June 5, 2024.
Director Cheryl R. Blanchard received stock options for 18,068 shares of Vigil Neuroscience, Inc. on June 5, 2024.
Stefan Vitorovic, a director at Vigil Neuroscience, had stock option awards repriced on May 3, 2024, according to a Form 4 filing with the SEC.
Director Bruce Booth receives repriced stock options from Vigil Neuroscience, Inc. under the 2021 Stock Option and Incentive Plan.
Christopher Verni, General Counsel of Vigil Neuroscience, repriced stock option awards to align with the company's fair market value as of May 3, 2024.
Director Suzanne Louise Bruhn of Vigil Neuroscience, Inc. reports repricing and grants of stock options, with exercise prices adjusted to the current fair market value.
David L.F. Gray, Chief Science Officer of Vigil Neuroscience, Inc., had his stock option award repriced to $3.03 per share on May 3, 2024, under the company's 2021 Stock Option and Incentive Plan.
Director Mary Thistle of Vigil Neuroscience, Inc. receives repriced stock option awards and new grants under the company's 2021 Stock Option and Incentive Plan.
Samantha L. Budd Haeberlein, a director at Vigil Neuroscience, received repriced stock options as part of the company's 2021 Stock Option and Incentive Plan.
Cheryl R. Blanchard, a director at Vigil Neuroscience, received repriced stock option awards on May 3, 2024, under the company's 2021 Stock Option and Incentive Plan.
Director Gerhard Koenig receives repriced stock options from Vigil Neuroscience, Inc. as part of the 2021 Stock Option and Incentive Plan.
Jennifer Lynn Ziolkowski, CFO of Vigil Neuroscience, receives repriced stock options and additional stock option awards under the company's 2021 Stock Option and Incentive Plan.
Ivana Magovcevic-Liebisch, President and CEO of Vigil Neuroscience, received repriced stock options on May 3, 2024, under the company's 2021 Stock Option and Incentive Plan.
Petra Kaufmann, Chief Medical Officer of Vigil Neuroscience, Inc., was granted stock options to purchase 330,000 shares of common stock on March 18, 2024.
Director Bruce Booth receives a stock option grant from Vigil Neuroscience in lieu of cash compensation.
Director Suzanne Bruhn received a stock option grant from Vigil Neuroscience in lieu of cash compensation.
Director Cheryl R. Blanchard of Vigil Neuroscience, Inc. was granted stock options in lieu of cash compensation, according to a recent SEC filing.
Christopher Verni, General Counsel of Vigil Neuroscience, reports the acquisition of stock options in the company.
Jennifer Lynn Ziolkowski, CFO of Vigil Neuroscience, Inc., was granted stock options to purchase 156,000 shares of common stock on March 1, 2024.
Ivana Magovcevic-Liebisch, President and CEO of Vigil Neuroscience, Inc., was granted a stock option to purchase 463,000 shares of common stock on March 1, 2024.
David L.F. Gray, Chief Science Officer of Vigil Neuroscience, Inc., was granted stock options to purchase 125,000 shares of common stock on March 1, 2024.